Table 1.

FDA Atomoxetine Dosing in Specific Populations: CYP2D6 Poor Metabolizers (2020)

Individual
Initial daily dose
Target total daily dose
Maximum total daily dose

Child or adolescent, up to 70 kg
0.5 mg/kg
1.2 mg/kg
1.4 mg/kg

Child or adolescent, up to 70 kg, known to be CYP2D6 PM
0.5 mg/kg
Only increase to the usual target dose of 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated
Not provided

Child or adolescent over 70 kg, or adults
40 mg
80 mg
100 mg

Child or adolescent over 70 kg, or adults, known to be CYP2D6 poor metabolizer
40 mg
Only increase to the usual target dose of 80 mg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated
Not provided

This FDA table is adapted from (1).

From: Atomoxetine Therapy and CYP2D6 Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.